Impact Factor
4.65
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
11.64
5,489 total citations
h5-index
142
h5 depth signal
Cited share
65.9%
334 of 507
Total citations
5,489
Citation footprint
Metric signal
12.91
External metric anchor
Self-citation
1.2%
66 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
908
United Kingdom
792
Australia
307
Canada
301
France
294
Citing Fields of Research
Respiratory Support
741
Allergies
438
Virology
402
Lung Cancer
265
Healthcare Policy
191
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,041
Articles tracked across the journal lifetime
Indexed publication set
507
334 cited publications
Last 12 months
239
19.9 publications/month
Open access share
10.5%
25 OA publications in the last year
Leading citing country
United States
908 citing publications
Leading citing field
Respiratory Support
741 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Mar. 2013-
v1n1, Mar. 2013-
Research Focus & Classification
Indexed Subjects
Allergies
Respiratory Support
Lung Cancer
Cystic Fibrosis
Auto-Inflammatory Disorders
Broad Categories
Pulmonary Medicine
Allergies
Respiratory Support
Cystic Fibrosis
Virology
Lung Cancer
Cardiology
MeSH Descriptors
Respiratory Tract Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/s2213-2600(26)00295-x
Open DOI
South Africa shifts away from salbutamol-only asthma relief
02
DOI 10.1016/s2213-2600(26)00203-1
Open DOI
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
03
04
DOI 10.1016/s2213-2600(26)00322-x
Open DOI
Preparedness for conflict in medical facilities
05
DOI 10.1016/s2213-2600(26)00314-0
Open DOI
European Respiratory Society International Congress 2026
06
DOI 10.1016/s2213-2600(26)00294-8
Open DOI
Medical oxygen supply in Zambia: beyond COVID-19
07
08
DOI 10.1016/s2213-2600(26)00278-x
Open DOI
Tuberculosis preventive treatment in high-burden settings: inequality in benefit, evidence, and potential harms
09
10
DOI 10.1016/s2213-2600(26)00226-2
Open DOI
Understanding US state-level heterogeneity in chronic respiratory disease burden
Bibliographical & Catalog Notes
Also issued online.